Advertisement
Screener

VERTEX PHARMACEUTICALS INC / MA (VRTX) APIC, Share-based Payment Arrangement, Increase for Cost Recognition

3.2 / 5 stars · 77/120 Roast Me

VERTEX PHARMACEUTICALS INC / MA APIC, Share-based Payment Arrangement, Increase for Cost Recognition

VERTEX PHARMACEUTICALS INC / MA (VRTX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $173.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Shareholders' Equity

us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-04

  • VERTEX PHARMACEUTICALS INC / MA apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $173.90M, a 1.58% increase year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $169.90M, a 0.53% increase year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $160.80M, a 5.91% decline year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $199.30M, a 5.90% increase year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $700.30M, a 1.24% decline from fiscal 2024.
  • VERTEX PHARMACEUTICALS INC / MA apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $709.10M, a 21.53% increase from fiscal 2023.
  • VERTEX PHARMACEUTICALS INC / MA apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $583.50M, a 18.98% increase from fiscal 2022.
  • VERTEX PHARMACEUTICALS INC / MA apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $490.40M, a 10.08% increase from fiscal 2021.
Period endAPIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 monthAPIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filedAPIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 monthAPIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month as first filedAPIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 monthAPIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month as first filedAPIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 monthAPIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed
2026-06-30$173.90M
10-Q · filed 2026-08-04
$343.80M
10-Q · filed 2026-08-04
$504.60M
derived: sum of 3 quarters · filed 2026-08-04
$703.90M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31$169.90M
10-Q · filed 2026-05-05
$330.70M
derived: sum of 2 quarters · filed 2026-05-05
$530.00M
derived: sum of 3 quarters · filed 2026-05-05
$701.20M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31$160.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13
$360.10M
derived: sum of 2 quarters · filed 2026-02-13
$531.30M
derived: sum of 3 quarters · filed 2026-08-04
$700.30M
10-K · filed 2026-02-13
2025-09-30$199.30M
10-Q · filed 2025-11-04
$370.50M
derived: sum of 2 quarters · filed 2026-08-04
$539.50M
10-Q · filed 2025-11-04
$710.40M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30$171.20M
10-Q · filed 2026-08-04
$340.20M
10-Q · filed 2026-08-04
$511.10M
derived: sum of 3 quarters · filed 2026-08-04
$699.30M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31$169.00M
10-Q · filed 2026-05-05
$339.90M
derived: sum of 2 quarters · filed 2026-05-05
$528.10M
derived: sum of 3 quarters · filed 2026-05-05
$685.10M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31$170.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13
$359.10M
derived: sum of 2 quarters · filed 2026-02-13
$516.10M
derived: sum of 3 quarters · filed 2026-02-13
$709.10M
10-K · filed 2026-02-13
2024-09-30$188.20M
10-Q · filed 2025-11-04
$345.20M
derived: sum of 2 quarters · filed 2025-11-04
$538.20M
10-Q · filed 2025-11-04
$747.30M
derived: sum of 4 quarters · filed 2026-02-13
2024-06-30$157.00M
10-Q · filed 2025-08-05
$350.00M
10-Q · filed 2025-08-05
$559.10M
derived: sum of 3 quarters · filed 2026-02-13
$690.80M
derived: sum of 4 quarters · filed 2026-02-13
2024-03-31$193.00M
10-Q · filed 2025-05-06
$402.10M
derived: sum of 2 quarters · filed 2026-02-13
$533.80M
derived: sum of 3 quarters · filed 2026-02-13
$653.70M
derived: sum of 4 quarters · filed 2026-02-13
2023-12-31$209.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13
$340.80M
derived: sum of 2 quarters · filed 2026-02-13
$460.70M
derived: sum of 3 quarters · filed 2026-02-13
$583.50M
10-K · filed 2026-02-13
2023-09-30$131.70M
10-Q · filed 2024-11-05
$251.60M
derived: sum of 2 quarters · filed 2024-11-05
$374.40M
10-Q · filed 2024-11-05
$485.40M
derived: sum of 4 quarters · filed 2025-02-13
2023-06-30$119.90M
10-Q · filed 2024-08-02
$242.70M
10-Q · filed 2024-08-02
$353.70M
derived: sum of 3 quarters · filed 2025-02-13
$489.00M
derived: sum of 4 quarters · filed 2025-02-13
2023-03-31$122.80M
10-Q · filed 2024-05-07
$233.80M
derived: sum of 2 quarters · filed 2025-02-13
$369.10M
derived: sum of 3 quarters · filed 2025-02-13
$482.70M
derived: sum of 4 quarters · filed 2025-02-13
2022-12-31$111.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13
$246.30M
derived: sum of 2 quarters · filed 2025-02-13
$359.90M
derived: sum of 3 quarters · filed 2025-02-13
$490.40M
10-K · filed 2025-02-13
2022-09-30$135.30M
10-Q · filed 2023-11-07
$248.90M
derived: sum of 2 quarters · filed 2023-11-07
$379.40M
10-Q · filed 2023-11-07
$498.30M
derived: sum of 4 quarters · filed 2024-02-15
2022-06-30$113.60M
10-Q · filed 2023-08-02
$244.10M
10-Q · filed 2023-08-02
$363.00M
derived: sum of 3 quarters · filed 2024-02-15
$466.70M
derived: sum of 4 quarters · filed 2024-02-15
2022-03-31$130.50M
10-Q · filed 2023-05-02
$249.40M
derived: sum of 2 quarters · filed 2024-02-15
$353.10M
derived: sum of 3 quarters · filed 2024-02-15
$459.00M
derived: sum of 4 quarters · filed 2024-02-15
2021-12-31$118.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15
$222.60M
derived: sum of 2 quarters · filed 2024-02-15
$328.50M
derived: sum of 3 quarters · filed 2024-02-15
$445.50M
10-K · filed 2024-02-15
2021-09-30$103.70M
10-Q · filed 2022-10-28
$103.65M
10-Q · filed 2021-11-03
$209.60M
derived: sum of 2 quarters · filed 2022-10-28
$326.60M
10-Q · filed 2022-10-28
$326.61M
10-Q · filed 2021-11-03
$424.19M
derived: sum of 4 quarters · filed 2023-02-10
2021-06-30$105.90M
10-Q · filed 2022-08-05
$105.92M
10-Q · filed 2021-07-30
$223.00M
10-Q · filed 2022-08-05
$222.95M
10-Q · filed 2021-07-30
$320.49M
derived: sum of 3 quarters · filed 2023-02-10
$420.98M
derived: sum of 4 quarters · filed 2023-02-10
2021-03-31$117.00M
10-Q · filed 2022-05-06
$117.04M
10-Q · filed 2021-04-30
$214.59M
derived: sum of 2 quarters · filed 2023-02-10
$315.08M
derived: sum of 3 quarters · filed 2023-02-10
$433.20M
derived: sum of 4 quarters · filed 2023-02-10
2020-12-31$97.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10
$198.08M
derived: sum of 2 quarters · filed 2023-02-10
$316.20M
derived: sum of 3 quarters · filed 2023-02-10
$433.10M
10-K · filed 2023-02-10
$433.07M
10-K · filed 2021-02-11
2020-09-30$100.49M
10-Q · filed 2021-11-03
$218.61M
derived: sum of 2 quarters · filed 2021-11-03
$335.51M
10-Q · filed 2021-11-03
$427.58M
derived: sum of 4 quarters · filed 2022-02-09
2020-06-30$118.12M
10-Q · filed 2021-07-30
$235.02M
10-Q · filed 2021-07-30
$327.09M
derived: sum of 3 quarters · filed 2022-02-09
$413.04M
derived: sum of 4 quarters · filed 2022-02-09
2020-03-31$116.90M
10-Q · filed 2021-04-30
$208.97M
derived: sum of 2 quarters · filed 2022-02-09
$294.92M
derived: sum of 3 quarters · filed 2022-02-09
$384.86M
derived: sum of 4 quarters · filed 2022-02-09
2019-12-31$92.07M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09
$178.02M
derived: sum of 2 quarters · filed 2022-02-09
$267.96M
derived: sum of 3 quarters · filed 2022-02-09
$362.20M
10-K · filed 2022-02-09
$362.21M
10-K · filed 2020-02-13
2019-09-30$85.96M
10-Q · filed 2020-10-30
$175.89M
derived: sum of 2 quarters · filed 2020-10-30
$270.13M
10-Q · filed 2020-10-30
$349.23M
derived: sum of 4 quarters · filed 2021-02-11
2019-06-30$89.94M
10-Q · filed 2020-07-31
$184.18M
10-Q · filed 2020-07-31
$263.28M
derived: sum of 3 quarters · filed 2021-02-11
$348.72M
derived: sum of 4 quarters · filed 2021-02-11
2019-03-31$94.24M
10-Q · filed 2020-05-01
$173.34M
derived: sum of 2 quarters · filed 2021-02-11
$258.78M
derived: sum of 3 quarters · filed 2021-02-11
$341.30M
derived: sum of 4 quarters · filed 2021-02-11
2018-12-31$79.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11
$164.54M
derived: sum of 2 quarters · filed 2021-02-11
$247.06M
derived: sum of 3 quarters · filed 2021-02-11
$325.66M
10-K · filed 2021-02-11
2018-09-30$85.44M
10-Q · filed 2019-10-31
$167.96M
derived: sum of 2 quarters · filed 2019-10-31
$246.56M
10-Q · filed 2019-10-31
$323.21M
derived: sum of 4 quarters · filed 2020-02-13
2018-06-30$82.52M
10-Q · filed 2019-08-01
$161.12M
10-Q · filed 2019-08-01
$237.77M
derived: sum of 3 quarters · filed 2020-02-13
$312.90M
derived: sum of 4 quarters · filed 2020-02-13
2018-03-31$78.60M
10-Q · filed 2019-05-01
$155.25M
derived: sum of 2 quarters · filed 2020-02-13
$230.39M
derived: sum of 3 quarters · filed 2020-02-13
$304.45M
derived: sum of 4 quarters · filed 2020-02-13
2017-12-31$76.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13
$151.78M
derived: sum of 2 quarters · filed 2020-02-13
$225.85M
derived: sum of 3 quarters · filed 2020-02-13
$295.64M
10-K · filed 2020-02-13
2017-09-30$75.13M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25
$149.20M
derived: sum of 2 quarters · filed 2018-10-25
$218.99M
10-Q · filed 2018-10-25
$278.95M
derived: sum of 4 quarters · filed 2019-02-13
2017-06-30$74.07M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26
$143.86M
10-Q · filed 2018-07-26
$203.82M
derived: sum of 3 quarters · filed 2019-02-13
$265.98M
derived: sum of 4 quarters · filed 2019-02-13
2017-03-31$69.79M
10-Q · filed 2018-04-27
$129.75M
derived: sum of 2 quarters · filed 2019-02-13
$191.91M
derived: sum of 3 quarters · filed 2019-02-13
$254.78M
derived: sum of 4 quarters · filed 2019-02-13
2016-12-31$59.96M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13
$122.13M
derived: sum of 2 quarters · filed 2019-02-13
$184.99M
derived: sum of 3 quarters · filed 2019-02-13
$241.24M
10-K · filed 2019-02-13
2016-09-30$62.16M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30
$125.03M
derived: sum of 2 quarters · filed 2017-10-30
$181.28M
10-Q · filed 2017-10-30
$226.69M
derived: sum of 4 quarters · filed 2018-02-15
2016-06-30$62.87M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28
$119.11M
10-Q · filed 2017-07-28
$164.53M
derived: sum of 3 quarters · filed 2018-02-15
$231.54M
derived: sum of 4 quarters · filed 2018-02-15
2016-03-31$56.25M
10-Q · filed 2017-04-28
$101.66M
derived: sum of 2 quarters · filed 2018-02-15
$168.68M
derived: sum of 3 quarters · filed 2018-02-15
$233.09M
derived: sum of 4 quarters · filed 2018-02-15
2015-12-31$45.41M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15
$112.43M
derived: sum of 2 quarters · filed 2018-02-15
$176.84M
derived: sum of 3 quarters · filed 2018-02-15
$235.11M
10-K · filed 2018-02-15
2015-09-30$67.02M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31
$131.43M
derived: sum of 2 quarters · filed 2016-10-31
$189.70M
10-Q · filed 2016-10-31
$232.60M
derived: sum of 4 quarters · filed 2017-02-23
2015-06-30$64.41M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01
$122.68M
10-Q · filed 2016-08-01
$165.58M
derived: sum of 3 quarters · filed 2017-02-23
$212.17M
derived: sum of 4 quarters · filed 2017-02-23
2015-03-31$58.27M
10-Q · filed 2016-05-03
$101.17M
derived: sum of 2 quarters · filed 2017-02-23
$147.76M
derived: sum of 3 quarters · filed 2017-02-23
$190.45M
derived: sum of 4 quarters · filed 2017-02-23
2014-12-31$42.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23
$89.49M
derived: sum of 2 quarters · filed 2017-02-23
$132.18M
derived: sum of 3 quarters · filed 2017-02-23
$178.97M
10-K · filed 2017-02-23
2014-09-30$46.59M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-30
$89.28M
derived: sum of 2 quarters · filed 2015-10-30
$136.06M
10-Q · filed 2015-10-30
$159.60M
derived: sum of 4 quarters · filed 2016-02-16
2014-06-30$42.69M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04
$89.47M
10-Q · filed 2015-08-04
$113.01M
derived: sum of 3 quarters · filed 2016-02-16
$144.52M
derived: sum of 4 quarters · filed 2016-02-16
2014-03-31$46.79M
10-Q · filed 2015-05-04
$70.32M
derived: sum of 2 quarters · filed 2016-02-16
$101.83M
derived: sum of 3 quarters · filed 2016-02-16
$143.56M
derived: sum of 4 quarters · filed 2016-02-16
2013-12-31$23.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16
$55.05M
derived: sum of 2 quarters · filed 2016-02-16
$96.78M
derived: sum of 3 quarters · filed 2016-02-16
$128.35M
10-K · filed 2016-02-16
2013-09-30$31.51M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06
$73.24M
derived: sum of 2 quarters · filed 2014-11-06
$104.82M
10-Q · filed 2014-11-06
$132.82M
derived: sum of 4 quarters · filed 2015-02-13
2013-06-30$41.73M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31
$73.31M
10-Q · filed 2014-07-31
$101.31M
derived: sum of 3 quarters · filed 2015-02-13
$129.23M
derived: sum of 4 quarters · filed 2015-02-13
2013-03-31$31.57M
10-Q · filed 2014-05-05
$59.58M
derived: sum of 2 quarters · filed 2015-02-13
$87.50M
derived: sum of 3 quarters · filed 2015-02-13
$119.17M
derived: sum of 4 quarters · filed 2015-02-13
2012-12-31$28.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13
$55.92M
derived: sum of 2 quarters · filed 2015-02-13
$87.60M
derived: sum of 3 quarters · filed 2015-02-13
$115.54M
10-K · filed 2015-02-13
2012-09-30$27.92M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07
$59.60M
derived: sum of 2 quarters · filed 2013-11-07
$87.54M
10-Q · filed 2013-11-07
$116.80M
derived: sum of 4 quarters · filed 2014-02-11
2012-06-30$31.68M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-02
$59.62M
10-Q · filed 2013-08-02
$88.88M
derived: sum of 3 quarters · filed 2014-02-11
$118.59M
derived: sum of 4 quarters · filed 2014-02-11
2012-03-31$27.94M
10-Q · filed 2013-05-08
$57.20M
derived: sum of 2 quarters · filed 2014-02-11
$86.91M
derived: sum of 3 quarters · filed 2014-02-11
$147.21M
derived: sum of 4 quarters · filed 2014-02-11
2011-12-31$29.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11
$58.97M
derived: sum of 2 quarters · filed 2014-02-11
$119.27M
derived: sum of 3 quarters · filed 2014-02-11
$119.27M
10-K · filed 2014-02-11
2011-09-30$29.71M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06
$90.00M
derived: sum of 2 quarters · filed 2012-11-06
$90.00M
10-Q · filed 2012-11-06
$141.61M
derived: sum of 4 quarters · filed 2013-03-01
2011-06-30$60.29M
10-Q · filed 2012-08-08
$60.29M
10-Q · filed 2012-08-08
$111.90M
derived: sum of 3 quarters · filed 2013-03-01
2011-03-31$28.03M
10-Q · filed 2012-05-10
$51.61M
derived: sum of 2 quarters · filed 2013-03-01
2010-12-31$23.57M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01
$91.12M
10-K · filed 2013-03-01
2010-09-30$67.55M
10-Q · filed 2011-11-03
2009-12-31$86.72M
10-K · filed 2012-02-22
2008-12-31$57.98M
10-K · filed 2011-02-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
PFIZER INC (PFE)United States$162.042B31.94
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64